RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Isolated data on the optimized groupFred wrote:
"Interesting topic - so cancer cells that have received an exceptional but not overwhelming dose of ROS can thereby be primed to be more resistant to subsequent exposure - something in the nature of a vaccine?"
My thinking is that, in general, a patient who receives an ROS-inducing treatment that is sub-therapeutic (either with regards to dosage &/or dosing frequency) could lead to two undesirable effects: 1). Promote resistance via the survival/growth of more highly ROS-adaptable cancer cells & 2). Cause an above baseline increase in intracellular ROS concentration that is non-toxic/non-lethal to a cancer cell, but that could possibly promote tumor development in any healthy cells that had sufficient uptake of drug to impact ROS levels detrimentally. This is why enhanced tumor selectivity (in addition to proper drug/MoA & dosing) is key. Fortunately, TLD1433/Rutherrin is highly selective for cancer cells...but clinically speaking, there's no treatment I'm aware of that's 100% selective.